Loading...
Thumbnail Image
Item

Effective NAION neuroregenerative treatment using TXA127

Advisor
Date
2024-05-04
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
Poster/Presentation
Research Area
Jurisdiction
Other Titles
See at
Abstract

Current approaches to treatment of nonarteritic anterior ischemic optic neuropathy (NAION) rely on early retinal ganglion cell (RGC) neuroprotection. However, current neuroprotective approaches have been ineffective when administered late (>1d) after induction in rodent and primate NAION models. This is particularly problematic clinically, since nearly all patients are diagnosed at least a day post-symptom onset. We report on the success of a new neuroregenerative approach using TXA127, a pharmaceutical formulation of angiotensin (1-7) currently in Phase II for ischemic stroke.

Data Availibility
Data / Code Location
Table of Contents
Description
Association for Vision and Ophthalmology (ARVO) convention. May 4, 2024.
Citations
Altmetric:
Series/Report No.
Sponsors
Rights/Terms
Attribution-NonCommercial-NoDerivatives 4.0 International
Identifier to cite or link to this item
Scopus Identifier
Embedded videos